Since the war began, lawmakers and commentators from both parties have questioned why the US struck the Islamic Republic and if the Trump administration was aware of potential problems in the Strait of Hormuz on the southern coast of Iran. President Donald Trump has said the US attacked largely because Iran was developing nuclear weapons, which threatened the US and Israel.
Since the war began, lawmakers and commentators from both parties have questioned why the US struck the Islamic Republic and if the Trump administration was aware of potential problems in the Strait of Hormuz on the southern coast of Iran. President Donald Trump has said the US attacked largely because Iran was developing nuclear weapons, which threatened the US and Israel.
Because in AI, supply chains are strategy. • Where are TSLA shares going? This Isn't About Chips — It's About Geography For years, Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) has been the default for cutting-edge semiconductors. Most of the AI world still runs through Taiwan. Tesla just stepped away from that gravity. Samsung's Taylor, Texas facility — set to produce Tesla's AI chip...
Because in AI, supply chains are strategy. • Where are TSLA shares going? This Isn't About Chips — It's About Geography For years, Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) has been the default for cutting-edge semiconductors. Most of the AI world still runs through Taiwan. Tesla just stepped away from that gravity. Samsung's Taylor, Texas facility — set to produce Tesla's AI chips starting 2027 — anchors a critical piece of Musk's stack firmly on U.S. soil. That's not just manufacturing. That's insulation. In a world where chip supply can be disrupted by geopolitics, shipping lanes or policy shifts, Tesla is quietly reducing a major risk: dependence on Asia. The Rise Of A ‘Sovereign' AI Supply Chain Tesla already designs its own silicon. Now it's pairing that with domestic manufacturing. Put the pieces together, and a pattern emerges: Design: in-house Manufacturing: U.S.-based Deployment: global This is what a sovereign chip chain looks like. It's not about beating TSMC on process nodes, at least not yet. It's about ensuring that Tesla's AI ambitions — from Full Self-Driving to Optimus — aren't bottlenecked by external dependencies. Why This Matters For The AI Race AI isn't just software anymore. Its hardware, energy, and infrastructure — all tightly coupled. If Tesla controls its chips, it controls the pace of its AI rollout. And that changes the competitive landscape. While others optimize for performance or cost, Tesla is optimizing for certainty — ensuring that the compute powering its vehicles and robots isn't stuck waiting in a fragile global supply chain. A Different Kind Of Power Play This isn't a rejection of TSMC. It's a signal. Tesla isn't just another customer in the semiconductor ecosystem — it's trying to become its own. And if that strategy works, the real advantage won't just be faster chips. It'll be having them when it matters most.
Broadcom Inc. (NASDAQ:AVGO) is one of the Jim Cramer’s Hottest AI Stock Picks. AI chip designer Broadcom Inc. (NASDAQ:AVGO) has shaped up to be one of the most important stocks in today’s AI era. Its shares are up by 67% over the past year and by 39% since Cramer discussed the firm in Mad Money aired on January 2nd. Several catalysts have driven the share price since then. For instance, Broadcom I...
Broadcom Inc. (NASDAQ:AVGO) is one of the Jim Cramer’s Hottest AI Stock Picks. AI chip designer Broadcom Inc. (NASDAQ:AVGO) has shaped up to be one of the most important stocks in today’s AI era. Its shares are up by 67% over the past year and by 39% since Cramer discussed the firm in Mad Money aired on January 2nd. Several catalysts have driven the share price since then. For instance, Broadcom Inc. (NASDAQ:AVGO)’s shares closed 9.4% higher on September 5th after the firm reported its fiscal third quarter earnings report. Not only did the results see the firm’s $15.9 billion in revenue and $1.69 in adjusted earnings beat analyst estimates of $15.83 billion and $1.65, but it also disclosed that it had secured a $10 billion order from an undisclosed customer for AI chips. Throughout 2025 and in 2026, Cramer has been one of Broadcom Inc. (NASDAQ:AVGO) CEO Hock Tan’s biggest supporters. The CNBC TV host believes that Tan is one of the toughest executives in the industry and is capable of steering his firm in today’s competitive environment. As early as January last year, Cramer was advising viewers to get into Broadcom Inc. (NASDAQ:AVGO)’s stock: Jim Cramer Was Bullish On Broadcom In January 2025 A semiconductor. Photo by Tima Miroshnichenko on Pexels “It’s very rare that you have a totally bankable exec [Tan] come on your show telling you exactly what will happen and then that executive delivers 100%. He’s greeted with disbelief, a giant upside surprise, and a gigantic move higher. He said it all. Plus, I think Broadcom’s in inning one of this turn. It’s not too late to get on board. This one, we have a nice slug for the Charitable Trust.” While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short...
Broadcom Inc. (NASDAQ:AVGO) is one of the Jim Cramer’s Hottest AI Stock Picks. AI chip designer Broadcom Inc. (NASDAQ:AVGO) has shaped up to be one of the most important stocks in today’s AI era. Its shares are up by 67% over the past year and by 39% since Cramer discussed the firm in Mad Money aired on January 2nd. Several catalysts have driven the share price since then. For instance, Broadcom I...
Broadcom Inc. (NASDAQ:AVGO) is one of the Jim Cramer’s Hottest AI Stock Picks. AI chip designer Broadcom Inc. (NASDAQ:AVGO) has shaped up to be one of the most important stocks in today’s AI era. Its shares are up by 67% over the past year and by 39% since Cramer discussed the firm in Mad Money aired on January 2nd. Several catalysts have driven the share price since then. For instance, Broadcom Inc. (NASDAQ:AVGO)’s shares closed 9.4% higher on September 5th after the firm reported its fiscal third quarter earnings report. Not only did the results see the firm’s $15.9 billion in revenue and $1.69 in adjusted earnings beat analyst estimates of $15.83 billion and $1.65, but it also disclosed that it had secured a $10 billion order from an undisclosed customer for AI chips. Throughout 2025 and in 2026, Cramer has been one of Broadcom Inc. (NASDAQ:AVGO) CEO Hock Tan’s biggest supporters. The CNBC TV host believes that Tan is one of the toughest executives in the industry and is capable of steering his firm in today’s competitive environment. As early as January last year, Cramer was advising viewers to get into Broadcom Inc. (NASDAQ:AVGO)’s stock: Jim Cramer Was Bullish On Broadcom In January 2025 A semiconductor. Photo by Tima Miroshnichenko on Pexels “It’s very rare that you have a totally bankable exec [Tan] come on your show telling you exactly what will happen and then that executive delivers 100%. He’s greeted with disbelief, a giant upside surprise, and a gigantic move higher. He said it all. Plus, I think Broadcom’s in inning one of this turn. It’s not too late to get on board. This one, we have a nice slug for the Charitable Trust.” While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short...
🔎 Micron Technology (MU): The memory-chip maker’s second-quarter revenue nearly tripled as AI-related demand for memory outpaces supply. Shares were down more than 4% in after-hours trading, after closing at an all-time high.
🔎 Micron Technology (MU): The memory-chip maker’s second-quarter revenue nearly tripled as AI-related demand for memory outpaces supply. Shares were down more than 4% in after-hours trading, after closing at an all-time high.
Teladoc (TDOC) closed at $5.42 in the latest trading session, marking a -3.39% move from the prior day. This move lagged the S&P 500's daily loss of 1.36%. At the same time, the Dow lost 1.64%, and the tech-heavy Nasdaq lost 1.46%. Shares of the telehealth services provider witnessed a gain of 23.03% over the previous month, beating the performance of the Medical sector with its loss of 5.66%, and...
Teladoc (TDOC) closed at $5.42 in the latest trading session, marking a -3.39% move from the prior day. This move lagged the S&P 500's daily loss of 1.36%. At the same time, the Dow lost 1.64%, and the tech-heavy Nasdaq lost 1.46%. Shares of the telehealth services provider witnessed a gain of 23.03% over the previous month, beating the performance of the Medical sector with its loss of 5.66%, and the S&P 500's loss of 1.76%. Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.3, marking a 57.89% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $612.3 million, down 2.71% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of -$0.86 per share and a revenue of $2.51 billion, demonstrating changes of +24.56% and -0.81%, respectively, from the preceding year. Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.93% higher. Teladoc presently features a Zacks Rank of #3 (Hold). The Medical Services industry is part of the Medical sector. ...
In the latest trading session, Wingstop (WING) closed at $191.17, marking a -3.49% move from the previous day. This move lagged the S&P 500's daily loss of 1.36%. Elsewhere, the Dow lost 1.64%, while the tech-heavy Nasdaq lost 1.46%. Shares of the restaurant chain witnessed a loss of 21.33% over the previous month, trailing the performance of the Retail-Wholesale sector with its loss of 0.82%, and...
In the latest trading session, Wingstop (WING) closed at $191.17, marking a -3.49% move from the previous day. This move lagged the S&P 500's daily loss of 1.36%. Elsewhere, the Dow lost 1.64%, while the tech-heavy Nasdaq lost 1.46%. Shares of the restaurant chain witnessed a loss of 21.33% over the previous month, trailing the performance of the Retail-Wholesale sector with its loss of 0.82%, and the S&P 500's loss of 1.76%. The investment community will be closely monitoring the performance of Wingstop in its forthcoming earnings report. The company is expected to report EPS of $1.05, up 6.06% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $190.48 million, up 11.33% from the year-ago period. WING's full-year Zacks Consensus Estimates are calling for earnings of $4.69 per share and revenue of $801.99 million. These results would represent year-over-year changes of +14.95% and +15.09%, respectively. Investors might also notice recent changes to analyst estimates for Wingstop. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.37% lower within the past month. Wingstop is holding a Zacks Rank of #3 (Hold) right now. In the context of valuation, Wingstop is at present trading with a Forward P/E ratio of 42.22. For comparison, its industry has an average Forwar...
In the latest trading session, Dominion Energy (D) closed at $62.20, marking a -1.32% move from the previous day. This move was narrower than the S&P 500's daily loss of 1.36%. Meanwhile, the Dow experienced a drop of 1.64%, and the technology-dominated Nasdaq saw a decrease of 1.46%. The stock of energy company has fallen by 3.99% in the past month, lagging the Utilities sector's gain of 0.07% an...
In the latest trading session, Dominion Energy (D) closed at $62.20, marking a -1.32% move from the previous day. This move was narrower than the S&P 500's daily loss of 1.36%. Meanwhile, the Dow experienced a drop of 1.64%, and the technology-dominated Nasdaq saw a decrease of 1.46%. The stock of energy company has fallen by 3.99% in the past month, lagging the Utilities sector's gain of 0.07% and the S&P 500's loss of 1.76%. The investment community will be closely monitoring the performance of Dominion Energy in its forthcoming earnings report. The company is forecasted to report an EPS of $0.87, showcasing a 6.45% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $4.26 billion, indicating a 4.48% increase compared to the same quarter of the previous year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.6 per share and a revenue of $16.74 billion, representing changes of +5.26% and +1.42%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Dominion Energy. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Dominion Energy currently has a Zacks Rank of #3 (Hold). With ...
The most recent trading session ended with Tilray Brands, Inc. (TLRY) standing at $1.89, reflecting a -1.56% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.14%, while the tech-heavy Nasdaq lost 0.06%. Prior to today's trading, shares of the company had gained 15.66% over the past month. This has outpaced the Consumer ...
The most recent trading session ended with Tilray Brands, Inc. (TLRY) standing at $1.89, reflecting a -1.56% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.14%, while the tech-heavy Nasdaq lost 0.06%. Prior to today's trading, shares of the company had gained 15.66% over the past month. This has outpaced the Consumer Staples sector's gain of 1.5% and the S&P 500's gain of 1.96% in that time. The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. The company's earnings report is expected on July 29, 2024. Meanwhile, the latest consensus estimate predicts the revenue to be $225.65 million, indicating a 22.51% increase compared to the same quarter of the previous year. It is also important to note the recent changes to analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Tilray Brands, Inc. possesses a Zacks Rank of #3 (Hold). The Consumer Products - Staples industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 193, which puts it in the bottom 24% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry...
In the latest close session, M/I Homes (MHO) was down 3.9% at $123.91. This change lagged the S&P 500's daily loss of 1.36%. On the other hand, the Dow registered a loss of 1.64%, and the technology-centric Nasdaq decreased by 1.46%. Coming into today, shares of the homebuilder had lost 12.13% in the past month. In that same time, the Construction sector lost 9.81%, while the S&P 500 lost 1.76%. I...
In the latest close session, M/I Homes (MHO) was down 3.9% at $123.91. This change lagged the S&P 500's daily loss of 1.36%. On the other hand, the Dow registered a loss of 1.64%, and the technology-centric Nasdaq decreased by 1.46%. Coming into today, shares of the homebuilder had lost 12.13% in the past month. In that same time, the Construction sector lost 9.81%, while the S&P 500 lost 1.76%. Investors will be eagerly watching for the performance of M/I Homes in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 22, 2026. The company is expected to report EPS of $2.64, down 33.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $929.65 million, down 4.76% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $13.63 per share and revenue of $4.48 billion, indicating changes of -7.53% and +1.36%, respectively, compared to the previous year. Investors should also take note of any recent adjustments to analyst estimates for M/I Homes. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, M/I Homes boasts a Zacks Rank of #4 (Sell). Investors should also n...
REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines...
REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines...
A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form ...
A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Financial Highlights Q4 2025 Highlights Total revenues 1 were $173 million, up 13% Year-on-Year (YoY) were $173 million, up 13% Year-on-Year (YoY) Adjusted EBITDA 1 was $69 million with Gross Margin at 66% was $69 million with Gross Margin at 66% AVT05 was approved as a biosimilar to Simponi® in the UK and European Economic Area (EEA) AVT03 was approved as a biosimilar to Prolia® and Xgeva® in the EEA The EMA accepted for review a marketing application for AVT23, referencing Xolair® After the end of the quarter, Alvotech entered into supply and commercialization agreements with Sandoz, covering multiple biosimilars candidates in Canada, Australia and New Zealand FY 2025 Highlights Total revenues 1 were $593 million, up 21% YoY were $593 million, up 21% YoY Adjusted EBITDA 1 was $137 million, up 27% YoY, with Gross Margin at 61% was $137 million, up 27% YoY, with Gross Margin at 61% The cash balance on December 31, 2025, was $172 million Second biosimilar in the US, Selarsdi™ referencing Stelara® launched by commercial partner Teva Three new biosimilars were approved in multiple markets, including the UK, EEA and Japan Alvotech acquired Xbrane’s R&D organization in Sweden and Ivers-Lee Group in Switzerland The company listed its shares on Nasdaq Stockholm and raised new equity Linda Jonsdottir was appointed Chief Financial Officer, Dr. Balaji V. Prasad was appointed Chief Strategy Officer, while Joseph McClellan transitioned into the role of Chief Operating Officer and Anthony Maffia into the role of Chief Regulatory and Quality Officer Comments by Chairman of the B...